ZURA BIO LIMITED Gain (Loss) on Investments
ZURA BIO LIMITED (ZURA) reported Gain (Loss) on Investments of $2.08 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-28.
Discontinued › Income Statement › Other Income
us-gaap:GainLossOnInvestments · last filed 2023-03-28
- ZURA BIO LIMITED gain (loss) on investments for the quarter ending 2022-12-31 was $1.19M.
- ZURA BIO LIMITED gain (loss) on investments for the quarter ending 2022-09-30 was $686.54K, a 9822.59% increase year-over-year.
- ZURA BIO LIMITED gain (loss) on investments for the quarter ending 2022-06-30 was $181.21K.
- ZURA BIO LIMITED gain (loss) on investments for the quarter ending 2022-03-31 was $16.30K.
- ZURA BIO LIMITED gain (loss) on investments for fiscal 2022 was $2.08M.
| Period end | Gain (Loss) on Investments 1 month | Gain (Loss) on Investments 3 month | Gain (Loss) on Investments 6 month | Gain (Loss) on Investments 7 month | Gain (Loss) on Investments 9 month | Gain (Loss) on Investments 10 month | Gain (Loss) on Investments 12 month |
|---|---|---|---|---|---|---|---|
| 2022-12-31 | $1.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $1.88M derived: sum of 2 quarters · filed 2023-03-28 | $2.06M derived: sum of 3 quarters · filed 2023-03-28 | $2.08M 10-K · filed 2023-03-28 | |||
| 2022-09-30 | $686.54K 10-Q · filed 2022-11-14 | $867.76K derived: sum of 2 quarters · filed 2022-11-14 | $884.06K 10-Q · filed 2022-11-14 | ||||
| 2022-06-30 | $181.21K 10-Q · filed 2022-08-12 | $197.51K 10-Q · filed 2022-08-12 | |||||
| 2022-03-31 | $16.30K 10-Q · filed 2022-05-13 | ||||||
| 2021-12-31 | $19.05K 10-K · filed 2023-03-28 | ||||||
| 2021-09-30 | $6.92K 10-Q · filed 2022-11-14 | $6.92K 10-Q · filed 2022-11-14 | |||||
| 2021-03-31 | $0.00 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |